Navigation Links
Abbott's XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
Date:9/21/2009

bal, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.

* Unless otherwise noted, all event rates and p-values are based on Kaplan-Meier estimates; p-values are for descriptive purposes only.

** Stent thrombosis rates are based on binary event rates, and p-values are based on Fisher's Exact Test; p-values are for descriptive purposes only.

*** Subgroup event rates are based on binary event rates.


'/>"/>
SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
2. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
3. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
4. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
5. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
6. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
7. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
8. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
9. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
10. Clinical Genomics Continues Progress in Developing Biomarker Portfolio for Colorectal Cancer Testing
11. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , July 2, 2015 The ... & Heterofermentative), Species (Lactobacillus, Pediococcus & Enterococcus), Enzymes (Fibre-digesting ... Forecast to 2020", Silage Inoculants & Enzymes Market is ... CAGR of 4.0% from 2015 to 2020. ... igures spread through 194 P ages ...
(Date:7/2/2015)... 2015 BGI gab heute bekannt, ... vom American College of Pathologists (CAP) akkreditiert ... erste klinische Next-Generation-Sequencing Labor, das in ... und somit die höchsten Standards an klinischer ... FDA - 21 CFR Part 11 konformen ...
(Date:7/2/2015)... Ill. , July 2, 2015  AbbVie (NYSE: ... results on Friday, July 24, 2015, before the market ... of the earnings conference call at 8 a.m. Central ... AbbVie,s Investor Relations website at www.abbvieinvestor.com . An ... 11 a.m. Central time. About AbbVie ...
Breaking Medicine Technology:Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 2Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 4BGI erhält Akkreditierung vom College of American Pathologists (CAP) 2
... , WALTHAM, ... the world,s leading research and advisory firms focusing on pharmaceutical ... market in Brazil will grow from $417 million in 2008 ... growth rate is attributed to a growing prevalent and drug-treated ...
... 3 New state investments will help an Adams ... facility and help a Philadelphia pharmaceutical distributor expand operations ... Rendell announced today. , The Pennsylvania Industrial Development Authority ... The investments, in the form of low-interest loans, will ...
Cached Medicine Technology:Brazil's Type 2 Diabetes Drug Market Will Grow to $834 Million by 2013 2Brazil's Type 2 Diabetes Drug Market Will Grow to $834 Million by 2013 3Governor Rendell: New State Investments Bear Fruit in Adams County; Help Pharmaceutical Company Expand in Philadelphia 2
(Date:7/2/2015)... CA (PRWEB) , ... July 02, 2015 , ... ... of Dr. Divakar R. Krishnareddy, M.D., to the orthopedic and spine surgery team ... disc herniations, sprains, strains, bursitis, and tendonitis. Along with the spine and spine ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... consulting services to the federal government, has announced they are among nine contractors ... Management Office Support Services (BMOSS) contract not to exceed $250 million. , ...
(Date:7/2/2015)... ... July 02, 2015 , ... B. E. Smith, the ... to lead a national chief executive officer recruitment for Indiana Blood ... healthcare industry, B. E. Smith has recently placed more than 1,000 healthcare executives ...
(Date:7/2/2015)... ... 2015 , ... AvePoint Public Sector, Inc., a wholly owned subsidiary ... today announced it was named the recipient of the 2015 GTRA ConVurge Tech Award ... by the Government Technology Research Alliance (GTRA), was presented June 29 during the ConVurge ...
(Date:7/2/2015)... Liverpool, Ohio (PRWEB) , ... July 02, 2015 , ... ... as Director of the Surgical Center at East Liverpool City Hospital (ELCH). Pam is ... assume the duties of the director of surgery. Pam holds a master’s degree in ...
Breaking Medicine News(10 mins):Health News:Healthpointe Welcomes Dr. Divakar R. Krishnareddy to its Orthopedic Team in Anaheim 2Health News:Healthpointe Welcomes Dr. Divakar R. Krishnareddy to its Orthopedic Team in Anaheim 3Health News:Octo Consulting Group Awarded IDIQ Contract for SEC Business Management Support 2Health News:Indiana Blood Center Retains B. E. Smith to Recruit New Chief Executive Officer 2Health News:Indiana Blood Center Retains B. E. Smith to Recruit New Chief Executive Officer 3Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 2Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 3Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 4Health News:East Liverpool City Hospital Announces New Surgical Center Leadership 2Health News:East Liverpool City Hospital Announces New Surgical Center Leadership 3
... better prognosis, study finds , , FRIDAY, Dec. 12 (HealthDay News) ... the risk of getting breast cancer, but women who take ... risk of dying from the disease, a new study suggests. ... particular type of cancer that is easier to treat," explained ...
... Ariz., Dec. 12 Roberta Kalafut, D.O., just announced her ... to a close the worst abuses of power by the ... unjust disciplinary actions, particularly against her competitors, and stonewalling by ... , "We applaud Kalafut,s resignation," said AAPS Executive ...
... Fair Offers New Chemists and Chemical Engineers an Opportunity to ... , PRINCETON, N.J., Dec. 12 Informex ... the upcoming InformexUSA exhibition in San Francisco free of charge. ... 25 and under to learn more about the chemical technologies ...
... saw disease stabilize or improve, study shows , , ... combination of medicines designed to boost immune function ... interim results from an ongoing Mayo Clinic study. ... immunomodulatory drug called pomalidomide with dexamethasone (pom/dex) improved ...
... At its 12th annual holiday gala The,Teddy Bear ... Award to Steve,Mosko, President of Sony Pictures Television ... to children with special needs. Grammy(R),winning singer-songwriter Kenny ... of the Heart. Long standing friend and colleague ...
... YORK, Dec. 12 In his last public remarks as,the ... Lilly and Company (NYSE: LLY ), today said ... markets and regulatory environments,encourage and reward companies for the long-term, ... bench to the bedside. , ...
Cached Medicine News:Health News:HRT Users Who Get Breast Cancer Less Likely to Die 2Health News:HRT Users Who Get Breast Cancer Less Likely to Die 3Health News:AAPS Applauds the Resignation of TMB President Roberta Kalafut, Mari Robinson Should Resign Next 2Health News:Informex Invites Young Chemists to Attend InformexUSA 2Health News:Informex Invites Young Chemists to Attend InformexUSA 3Health News:Combo Therapy Helps Multiple Myeloma Patients 2Health News:The Help Group's Teddy Bear Ball Salutes Sony Pictures Television President, Steve Mosko and Features Performance by Kenny Loggins 2Health News:Lilly Chairman Taurel Says Promise of Personalized Medicine Could be Jeopardized by Short-Sighted Public Policies 2Health News:Lilly Chairman Taurel Says Promise of Personalized Medicine Could be Jeopardized by Short-Sighted Public Policies 3
... is a high precision optical system for ... the anterior eye segment, based on a ... Placido Disk. , GALILEI combines the advantages ... accuracy curvature data, while Scheimpflug imaging is ...
... The C-VUE 55 Toric Multifocal ... also have presbyopia with all day ... visual acuity at every distance. This ... wide range of parameters with ADDs ...
... Nicknamed the SRS, this new and innovative stent ... the office right at the chair with just ... medical grade silicone and is available in three ... separately). At each end of the stent is ...
... Using flying spot technology the Technolas 217z ... for personalized vision correction, allows surgeons in ... to -7.00 Diopters and astigmatism up to ... combines both a 2mm and 1mm truncated ...
Medicine Products: